Cargando…
Selective Activator of the Glucocorticoid Receptor Compound A Dissociates Therapeutic and Atrophogenic Effects of Glucocorticoid Receptor Signaling in Skin
BACKGROUND: Glucocorticoids are effective anti-inflammatory drugs widely used in dermatology and for the treatment of blood cancer patients. Unfortunately, chronic treatment with glucocorticoids results in serious metabolic and atrophogenic adverse effects including skin atrophy. Glucocorticoids act...
Autores principales: | Klopot, Anna, Baida, Gleb, Bhalla, Pankaj, Haegeman, Guy, Budunova, Irina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Cancer Prevention
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4699752/ https://www.ncbi.nlm.nih.gov/pubmed/26734587 http://dx.doi.org/10.15430/JCP.2015.20.4.250 |
Ejemplares similares
-
Sexual dimorphism in atrophic effects of topical glucocorticoids is driven by differential regulation of atrophogene REDD1 in male and female skin
por: Baida, Gleb, et al.
Publicado: (2020) -
Deletion of the glucocorticoid receptor chaperone FKBP51 prevents glucocorticoid-induced skin atrophy
por: Baida, Gleb, et al.
Publicado: (2018) -
Discovery of Compound A – a selective activator of the glucocorticoid receptor with anti-inflammatory and anti-cancer activity
por: Lesovaya, Ekaterina, et al.
Publicado: (2015) -
REDD1 functions at the crossroads between the therapeutic and adverse effects of topical glucocorticoids
por: Baida, Gleb, et al.
Publicado: (2015) -
Important role of kallikrein 6 for the development of keratinocyte proliferative resistance to topical glucocorticoids
por: Kishibe, Mari, et al.
Publicado: (2016)